Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Completes Strategic Review, Rejects Acquisition Offers

NEW YORK – Qiagen announced earlier this week that it has completed a strategic review, and after receiving interest from unnamed parties, the firm has decided to remain a stand-alone business.

In reaction to the news, which was announced after the early close of the stock market on Christmas Eve, shares of Qiagen fell 21 percent to close at $32.91 in Thursday trade on the New York Stock Exchange.

The review began in mid-November after it received several "conditional, non-binding indications of interest" from potential merger or acquisition partners. Those expressions of interest came in the wake of the firm announcing that its long-time CEO Peer Schatz would step down, that it had lowered third quarter sales growth expectations, and that it would it would suspend ongoing next-gen sequencing-related instrument development while announcing a 15-year partnership with Illumina to develop next-generation sequencing-based in vitro diagnostic kits, including companion diagnostics.

One of the firms reported to have reached out to Qiagen regarding a potential acquisition was Thermo Fisher Scientific.

However, Qiagen said this week that its supervisory board and management board determined that the various alternatives to its prospects as a stand-alone company were not compelling, and it has "terminated all discussions so that full management focus can be on executing the stand-alone plan."

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.